If you would like to contact Teva Respiratory, you may call:
Patients using AirDuo Digihaler should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason
ArmonAir Digihaler inhalation powder is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.
Limitation of Use: ArmonAir Digihaler is not indicated for the relief of acute bronchospasm.
AirDuo Digihaler inhalation powder is indicated for the treatment of asthma in patients 12 years of age and older. AirDuo Digihaler is only for patients uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants an ICS/Long-acting beta2-agonist (LABA).
Limitation of Use: AirDuo Digihaler is not indicated for the relief of acute bronchospasm.
ArmonAir Digihaler and AirDuo Digihaler contain a built-in electronic module which detects, records, and stores data on inhaler events for transmission to mobile App. Use of the App is not required for administration of medication to the patient.
ProAir Digihaler Inhalation Powder is indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients 4 years of age and older for the prevention of exercise-induced bronchospasm.
ProAir Digihaler contains a built-in electronic module that detects, records and stores inhaler event information. ProAir Digihaler may be used with, and transmits information to, a mobile app. Use of the mobile app is not required for administration of medication to the patient.
Please see full Prescribing Information for ProAir Digihaler.
References: 1. ProAir Digihaler. Prescribing Information. Teva; 2022. Accessed July 1, 2022. https://www.digihalerhcp.com/globalassets/
proair_digihaler_pi.pdf 2. AirDuo Digihaler. Prescribing information. Teva; 2022. Accessed July 1, 2022. https://
airduo_digihaler/airduo_digihaler_pi.pdf 3. ArmonAir Digihaler. Prescribing Information. Teva; 2022. Accessed July 1, 2022. https://
armonair_digihaler/armonair_digihaler_pi.pdf 4. Sulaiman I, Seheult J, MacHale E, et al. Irregular and ineffective: a quantitative observational study of the time and technique of inhaler use. J Allergy Clin Immunol Pract. 2016;4(5):900-909. 5. Patel M, Perrin K, Pritchard A, et al. Accuracy of patient self-report as a measure of inhaled asthma medication use. Respirology. 2013;18(3):546-552. 6. Unni E, Gabriel S, Ariely R. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol. 2018;121(6):680-691. 7. Silver HS, Blanchette CM, Kamble S, et al. Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United States. J Asthma. 2010;47(6):660-666. 8. Azzi EA, Kritikos V, Peters MJ, et al. Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey. BMJ Open. 2019;9(8):e028995. 9. Hoyte FCL, Mosnaim GS, Rogers L, et al. Effectiveness of a digital inhaler system for patients with asthma: a 12-week, open-label, randomized study (CONNECT1). J Allergy Clin Immunol Pract. 2022;10(10):2579-2587. 10. Advair Diskus Prescribing Information. GSK; 2020. Accessed September 13 2022. https://gskpro.com/
ADVAIR-DISKUS-PI-PIL-IFU.PDF 11. Flovent HFA Prescribing Information. GSK; 2022. Accessed September 13, 2022. https://gskpro.com/
FLOVENT-HFA-PI-PIL-IFU.PDF 12. Flovent Diskus Prescribing Information. GSK; 2022. Accessed September 13, 2022. https://gskpro.com/
PIL-IFU.PDF 13. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930-938. 14. Data on File. Frazer, PA: Teva Respiratory, LLC. 15. Brooke J. SUS: a “quick and dirty” usability scale. In Jordan PW, Thomas B, Weerdmeester BA, McClelland IL, eds. Usability Evaluation in Industry. Taylor & Francis Ltd; 1996:189-194.
You are about to leave DigihalerHCP.com and enter a website operated by a third party.
Would you like to continue?
Due to technical changes in Google policies, the Digihaler app was temporarily removed from the Google Play Store.
We are working on an update and will publish a new version soon. If you would like more information or a notification when the app is available again, please call our team at 888-603-0788.
Note: This does not affect the Apple App Store.